Yimei Han
Overview
Explore the profile of Yimei Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
581
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, Huo Y, Xie R, Han Y, Zou H, Wang Y
Int Ophthalmol
. 2025 Jan;
45(1):55.
PMID: 39890674
Purpose: To evaluate corneal tomography asymmetry of both eyes in keratoconus (KC), keratoconus suspects (KCS), and normal (NL) eyes, and to introduce an interocular asymmetry index (IAI) for early diagnosis...
2.
Yan S, Han Y, Wu G
Aesthetic Plast Surg
. 2025 Jan;
PMID: 39821296
Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the...
3.
Han Y, Liu C, Wu G
Aesthetic Plast Surg
. 2024 Aug;
48(22):4675-4686.
PMID: 39093359
Background: With the increasing use of autologous fat (AF) grafting in plastic surgery, the occurrence of complications has garnered the attention from plastic surgeons. This study aims to estimate the...
4.
De Braud F, Deschler-Baier B, Morris 3rd J, Worden F, Han Y, Kiiskinen U, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201566
Selpercatinib is indicated for locally advanced/metastatic -activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data...
5.
Smyth E, John J, Tiu R, Willard M, Beyrer J, Bowman L, et al.
Oncologist
. 2023 Jun;
28(11):e1075-e1091.
PMID: 37358877
Background: This retrospective, real-world study evaluated the prevalence of brain metastases, clinicodemographic characteristics, systemic treatments, and factors associated with overall survival among patients with advanced non-small cell lung cancer (aNSCLC)...
6.
Hess L, Han Y, Zhu Y, Bhandari N, Sireci A
BMC Cancer
. 2023 Apr;
23(1):382.
PMID: 37101117
No abstract available.
7.
Aggarwal H, Bayo K, Han Y, Muehlenbein C, Zhu Y, Kim J
Immunotherapy
. 2023 Feb;
15(4):267-281.
PMID: 36789638
To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous non-small-cell lung cancer (NSQ-NSCLC) patients that received pembrolizumab plus pemetrexed-platinum (pembro+pem+plat) aligned with KEYNOTE-189. OS was evaluated...
8.
Aggarwal H, Han Y, Sheffield K, Cui Z
J Comp Eff Res
. 2023 Jan;
12(2):e220143.
PMID: 36705061
This real-world study aims to compare overall survival (OS) associated with biweekly (Q2W) versus weekly (Q1W) cetuximab dosing regimens for metastatic colorectal cancer (mCRC) treatment in the US. Adult patients...
9.
Hess L, Krein P, Haldane D, Han Y, Sireci A
JTO Clin Res Rep
. 2022 Jun;
3(6):100336.
PMID: 35677681
Introduction: NSCLC is a solid tumor with a growing number of actionable biomarkers that may inform treatment. Current guidelines recommend a broad, panel-based approach be taken to identify actionable markers....
10.
Hirata K, Ueda K, Komori M, Zagar A, Selzler K, Nelson A, et al.
Curr Med Res Opin
. 2021 Aug;
37(11):1945-1955.
PMID: 34429000
Objective: The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVERCOME [Japan]) aimed to provide an up-to-date assessment of migraine epidemiology in Japan. Methods: OVERCOME...